The Effect of O6-methylguanine-DNA methyltransferase (MGMT) and mismatch repair gene (hMLH1) status on the sensitivity to alkylating agent 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU) in gallbladder carcinoma cells

Anticancer Research

Volumn 25, Issue 6 B, 2005, Pages 4021-4028

  Sato, Ken ^a   Kitajima, Yoshihiko ^a   Koga, Yasuo ^a   Miyazaki, Kohji ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

ACNU; Alkylating agents; Gallbladder carcinoma; hMLH1; MGMT

Indexed keywords

ALKYLATING AGENT; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NIMUSTINE; PROTEIN MLH1; CARRIER PROTEIN; MLH1 PROTEIN, HUMAN; NUCLEAR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GALLBLADDER CARCINOMA; HUMAN; HUMAN CELL; MISMATCH REPAIR; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BASE MISPAIRING; BIOSYNTHESIS; DNA REPAIR; DRUG SCREENING; ENZYMOLOGY; GALLBLADDER TUMOR; GENETICS; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BASE PAIR MISMATCH; CARRIER PROTEINS; CELL LINE, TUMOR; DNA REPAIR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NIMUSTINE; NUCLEAR PROTEINS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; RNA, MESSENGER;

EID: 27944497740     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Tazuma S and Kajiyama G: Carcinogenesis of malignant lesions of the gallbladder. The impact of chronic inflammation and gallstones. Langenbeck's Arch Surg 386: 224-229, 2001.
2. 6-methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMLH2 is related to poor prognosis in human biliary tract carcinoma. Ann Surg Oncol 9: 371-379, 2002.
3. Hemminki K and Ludlum DB: Covalent modification of DNA by antineoplastic agents. J Natl Cancer Inst 73: 1021-1028, 1984.
4. Eisenbrand G, Pfeiffer C and Tang W: DNA adducts of N-nitrosoureas. In: DNA Adducts: Identification and Biological Significance, Hemminki K et al. (eds.). IARC Scientific Publications no. 125. IARC, Lyon, pp. 277-293, 1994.
5. Hemminki K: DNA adducts of nitrogen mustards and ethylene imines. In: DNA Adducts: Identification and Biological Significance, Hemminki K et al. (eds.). IARC Scientific Publications no. 125. IARC, Lyon, pp. 313-321, 1994.
6. Michejda CJ, Smith RH Jr and Kroeger-Koepke MB: DNA alkylation by triazenes and related compounds. In: DNA Adducts: Identification and Biological Significance, Hemminki K et al. (eds.). IARC Scientific Publications no. 125. IARC, Lyon, pp. 323-337, 1994.
7. Gerson SL: MGMT: Its role in cancer aetiology and cancer therapeutics. Nature Rev Cancer 4: 296-307, 2004.
8. Lindahl T, Sedgwick B, Sekiguchi M and Nakabuppu Y: Regulation and expression of the adaptive response to alkylating agents. Annu Rev Biochem 57: 133-157, 1998.
9. 6-methylguanine to a protein cysteine residue. J Biol Chem 255: 10569-10571, 1980.
10. Sekiguchi M and Nakabeppu Y: Adaptive response: induced synthesis of DNA repair enzymes by alkylating agents. Trends Genet 3: 51-54, 1987.
11. 6-methylguanine- DNA methyltransferase. Nucleic Acids Res 11: 7743-7758, 1983.
12. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB and Herman JG: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. New Engl J Med 343: 1350-1354, 2000.
13. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50: 6119-6129, 1990.
14. Gerson SL: Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20: 2388-2399, 2002.
15. Fink D, Aebi S and Howell SB: The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4: 1-6, 1998.
16. D'atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, Zambruno G, Bonimassar E and Jiricny J: Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 54: 334-341, 1998.
17. Kat A, Thilly WG, Fang WH, Longley MJ, Li GM and Modrich P: An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA 90: 6424-6428, 1993.
18. Liu L, Markowitz S and Gerson SL: Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-Bis(2-chloroethyl)nitrosourea. Cancer Res 56: 5375-5379, 1996.
19. Geran RI, Greenberg NH, Macdonald MM, Schumacher AM and Abbort BJ: Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 3: 51-61, 1972.
20. Taner CB, Nagorney DM and Donobue FH: Surgical treatment of gallbladder cancer. J Gastrointest Surg 8: 83-89, 2004.
21. Todoroki T: Chemotherapy for gallbladder carcinoma - a surgeon's perspective. Hepato-gastroenterology 47: 948-955, 2000.
22. Takada T and Uchiyama K: Chemotherapy for unresectable biliary cancer. Kan Tan Sui (In Japanese) 25: 695-699, 1992.
23. Taal BG, Audisio RA, Bleiberg H, Blijham GH, Neijt JP, Veenhof CH Duez N and Sahmoud T: Phase II trial of mitomycin(MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC gastrointestinal tract cancer cooperative group study. Ann Oncol 4: 607-609, 1993.
24. Okada S, Ishii H, Nose H, Yoshimori M, Okusaka T, Aoki K, Iwasaki M, Furuse J and Yoshino M: A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology 57: 515-517, 1994.
25. Sanz-Altamira PM, Ferrante K, Jenkins RL, Lewis WD, Huberman MS and Stuart KE: A phase II study of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 82: 2321-2325, 1998.
26. Kawate H, Sakumi K, Tsuzuki T, Nakatsuru Y, Ishikawa T, Takahashi S, Takano H, Noda T and Sekiguchi M: Separation killing and tumorigenic effects of an alkylating agent in mice defective in two of the DNA repair genes. Proc Natl Acad Sci 95: 5116-5120, 1998.
27. Saito T, Yokoyama M, Himori T, Ujiie S, Sugawara N, Sugiyama Z and Kitada K: Phase I and preliminary phase II study of 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) administered by intermittent dose schedule. Jpn J Cancer Chemother 4: 991-1004, 1977.
28. 6-methylguanine in DNA to inactivation by alkylating agents including chloroethylnitrosoureas. Cancer Res 44: 2467-2474, 1984.
29. Jacob S and Praz F: DNA mismatch repair defects: role in colorectal carcinogenesis. Biochimie 84: 27-47, 2002.
30. Hickman MJ and Samson LD: Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc Natl Acad Sci USA 96: 10764-10769, 1999.
31. Wu J, Gu L Wang H, Geacintov NE and Li GM: Mismatch repair processing of carcinogen-DNA adducts triggers apoptosis. Mol Cell Biol 19: 8292-8301, 1999.
32. 6- alkylguanine-DNA alkyltransferase becomes covalently bound to DNA containing, 1,3-bis(2-chloro-ethyl)-1-nitrosourea - induced precursors of interstrand cross-links. Biochem Biophys Res Commun 142: 341-347, 1987.
33. Srivenugopal KD: Formation and disappearance of DNA interstrand cross-links in human colon tumor cell lines with different levels of resistance to chlorozotocin. Biochem Phrmacol 433: 1159-1163, 1992.
34. 6-alkylguanine-DNA alkyltransferase in limiting nitrosourea induced sister chromatid exchanges in proliferating human lymphocytes. Cancer Res 49: 1899-1903, 1989.